{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:59:00Z","timestamp":1771210740322,"version":"3.50.1"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Tr"],"published-print":{"date-parts":[[1995]]},"DOI":"10.1007\/bf00713399","type":"journal-article","created":{"date-parts":[[2004,12,2]],"date-time":"2004-12-02T03:45:03Z","timestamp":1101959103000},"page":"267-285","source":"Crossref","is-referenced-by-count":127,"title":["?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"V. Craig","family":"Jordan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4684-3237-4_7","volume-title":"Receptors for Reproductive Hormones. Advances in Experimental Medicine and Biology","author":"WL McGuire","year":"1973","unstructured":"McGuire WL, Chamness GC: Studies on the estrogen receptor in breast cancer. In: O'Malley BW, Means AR (eds) Receptors for Reproductive Hormones. Advances in Experimental Medicine and Biology, Plenum Press, New York, 1973, Vol. 37, pp 113?136."},{"key":"CR2","first-page":"387","volume":"18","author":"EV Jensen","year":"1962","unstructured":"Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen actions. Recent Prog Horm Res 18:387?414, 1962.","journal-title":"Recent Prog Horm Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0039-128X(94)90107-4","volume":"59","author":"J Gorski","year":"1994","unstructured":"Gorski J: A hindsight view of early studies on the estrogen receptor: a personal history. Steroids 59:240?243, 1994.","journal-title":"Steroids"},{"key":"CR4","volume-title":"Estrogen Receptors in Human Breast Cancer","year":"1975","unstructured":"McGuire WL, Carbone PP, Vollmer EP (eds): Estrogen Receptors in Human Breast Cancer. Raven Press, New York, 1975."},{"key":"CR5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.168640","volume":"189","author":"KB Horwitz","year":"1975","unstructured":"Horwitz KB, McGuire WL, Pearson OH, Segaloff A: Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science 189:726?727, 1975.","journal-title":"Science"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0039-128X(75)90110-5","volume":"26","author":"KB Horwitz","year":"1975","unstructured":"Horwitz KB, Costlow ME, McGuire WL: MCF-7: A human breast cancer cell line with estrogen, androgen, progesterone and glucocorticoid receptor. Steroids 26:785?795, 1975.","journal-title":"Steroids"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(17)38062-6","volume":"253","author":"KB Horwitz","year":"1978","unstructured":"Horwitz KB, McGuire WL: Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 253:2223?2228, 1978.","journal-title":"J Biol Chem"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1210\/endo-103-5-1742","volume":"103","author":"KB Horwitz","year":"1978","unstructured":"Horwitz KB, Koseki Y, McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology 103:1742?1751, 1978.","journal-title":"Endocrinology"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1002\/1097-0142(19801215)46:12+<2884::AID-CNCR2820461429>3.0.CO;2-U","volume":"46","author":"CK Osborne","year":"1980","unstructured":"Osborne CK, Yochmowitz MG, Knight WA, McGuire WL: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer Res 46:2884?2888, 1980.","journal-title":"Cancer Res"},{"key":"CR10","first-page":"341","volume-title":"Estrogen\/Antiestrogen Action and Breast Cancer Therapy","author":"CJ LeMaistre","year":"1986","unstructured":"LeMaistre CJ, McGuire WL: Progesterone receptor determinations: a refinement of predictive tests for hormone dependency of breast cancer.In: Jordan VC (ed) Estrogen\/Antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press, Madison, 1986, pp 341?354."},{"key":"CR11","first-page":"4669","volume":"37","author":"WA Knight III","year":"1977","unstructured":"Knight WA III, Livingston RB, Gregory EJ, McGuire WL: Estrogen receptor is an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669?4671, 1977.","journal-title":"Cancer Res"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM198312013092240","volume":"309","author":"GM Clark","year":"1983","unstructured":"Clark GM, McGuire WL, Hubay CA, Pearson OH, Marshall JS: Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 309:1343?1347, 1983.","journal-title":"N Engl J Med"},{"key":"CR13","first-page":"105","volume":"51","author":"SAW Fuqua","year":"1991","unstructured":"Fuqua SAW, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O'Malley BW, McGuire WL: Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51:105?109, 1991.","journal-title":"Cancer Res"},{"key":"CR14","first-page":"482","volume":"52","author":"SAW Fuqua","year":"1992","unstructured":"Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, McDonnell DP, O'Malley BW, Greene GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52:482?486, 1992.","journal-title":"Cancer Res"},{"key":"CR15","first-page":"3","volume-title":"Long-Term Tamoxifen Treatment for Breast Cancer","author":"VC Jordan","year":"1994","unstructured":"Jordan VC: The development of tamoxifen for breast cancer therapy.In: Jordan VC (ed) Long-Term Tamoxifen Treatment for Breast Cancer. University of Wisconsin Press, Madison, 1994, pp 3?26."},{"key":"CR16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1210\/endo-63-3-295","volume":"63","author":"LJ Lerner","year":"1958","unstructured":"Lerner LJ, Holthaus JF, Thompson CR: A nonsteroid estrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl-ethanol. Endocrinology 63:295?318, 1958.","journal-title":"Endocrinology"},{"key":"CR17","first-page":"1","volume-title":"Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity","author":"LJ Lerner","year":"1981","unstructured":"Lerner LJ: The first nonsteroidal antioestrogen ? MER25.In: Sutherland RL, Jordan VC (eds) Nonsteroidal Antioestrogens: Molecular Pharmacology and Antitumour Activity. Academic Press, Sydney, 1981, pp 1?16."},{"key":"CR18","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3181\/00379727-105-26054","volume":"105","author":"DE Holtkamp","year":"1960","unstructured":"Holtkamp DE, Greslin SC, Root CA, Lerner LJ: Gonadotropin inhibiting and antifecundity effects of clomiphene. Proc Soc Exp Biol Med 105:197?201, 1960.","journal-title":"Proc Soc Exp Biol Med"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0015-0282(16)43749-0","volume":"31","author":"LC Huppert","year":"1979","unstructured":"Huppert LC: Induction of ovulation with clomiphene citrate. Fert Steril 31:1?8, 1979.","journal-title":"Fert Steril"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/jrf.0.0130101","volume":"13","author":"MJK Harper","year":"1967","unstructured":"Harper MJK, Walpole AL: A new derivative of triphenylethylene: effect on implantation in rats. J Reprod Fertil 13:101?119, 1967.","journal-title":"J Reprod Fertil"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1677\/joe.0.0370083","volume":"37","author":"MJK Harper","year":"1967","unstructured":"Harper MJK, Walpole AL: Mode of action of ICI 46,474 in preventing implantation in rats. J Endocrinol 37:83?92, 1967.","journal-title":"J Endocrinol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/endo-87-3-542","volume":"87","author":"AP Labsetwar","year":"1970","unstructured":"Labsetwar AP: Role of estrogen in ovulation. A study using the estrogen antagonist ICI 46,474. Endocrinology 87:542?551, 1970.","journal-title":"Endocrinology"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/bmj.1.5741.152","volume":"i","author":"A Klopper","year":"1971","unstructured":"Klopper A, Hall M: New synthetic agent for the induction of ovulation: preliminary trials in women. Br Med J i:152?154, 1971.","journal-title":"Br Med J"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.1972.tb00399.x","volume":"1","author":"Z El-Sheika","year":"1972","unstructured":"El-Sheika Z, Klopper A, Beck JS: Treatment of menometrorrhagia with an antioestrogen. Clin Endocrinol 1:275?282, 1972.","journal-title":"Clin Endocrinol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1471-0528.1973.tb11230.x","volume":"80","author":"JG Williamson","year":"1973","unstructured":"Williamson JG, Ellis JP: The induction of ovulation by tamoxifen. J Obstet Gynaecol Br Commonwealth 80:844?847, 1973.","journal-title":"J Obstet Gynaecol Br Commonwealth"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0028-2243(75)90022-2","volume":"415","author":"MM Shaaban","year":"1975","unstructured":"Shaaban MM: Suppression of lactation by an antioestrogen tamoxifen. Eur J Obstet Gynaecol Reprod Biol 415:167?169, 1975.","journal-title":"Eur J Obstet Gynaecol Reprod Biol"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/bjc.1971.33","volume":"25","author":"M Cole","year":"1971","unstructured":"Cole M, Jones CT, Todd IDH: A new antioestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474. Br J Cancer 25:270?275, 1971.","journal-title":"Br J Cancer"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.1.5844.13","volume":"i","author":"HWC Ward","year":"1973","unstructured":"Ward HWC: Antioestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J i:13?14, 1973.","journal-title":"Br Med J"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1677\/joe.0.0520289","volume":"52","author":"J Skidmore","year":"1972","unstructured":"Skidmore J, Walpole AL, Woodburn J: Effect of some triphenylethylenes on oestradiol bindingin vitro to macromolecules from uterus and anterior pituitary. J Endocrinol 52:289?298, 1972.","journal-title":"J Endocrinol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0014-2964(75)90119-X","volume":"11","author":"VC Jordan","year":"1975","unstructured":"Jordan VC, Koerner S: Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11:205?206, 1975.","journal-title":"Eur J Cancer"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0022-4731(74)90388-4","volume":"5","author":"VC Jordan","year":"1974","unstructured":"Jordan VC: Antitumour activity of the antioestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354, 1974.","journal-title":"J Steroid Biochem"},{"key":"CR32","first-page":"11","volume-title":"The antitumour effect of tamoxifen in the dimethylbenzanthracene-induced mammary carcinoma model. Proc Symp Horm Control Breast Cancer","author":"VC Jordan","year":"1975","unstructured":"Jordan VC: The antitumour effect of tamoxifen in the dimethylbenzanthracene-induced mammary carcinoma model. Proc Symp Horm Control Breast Cancer. ICI Pharmaceuticals Ltd, Alderley Park, Macclesfield, 1975, pp 11?17."},{"key":"CR33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/0014-2964(75)90129-2","volume":"11","author":"RI Nicholson","year":"1975","unstructured":"Nicholson RI, Golder MP: The effect of synthetic antioestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer 11:571?579, 1975.","journal-title":"Eur J Cancer"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0014-2964(76)90030-X","volume":"12","author":"VC Jordan","year":"1976","unstructured":"Jordan VC: Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419?424, 1976.","journal-title":"Eur J Cancer"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/joe.0.0680297","volume":"68","author":"VC Jordan","year":"1976","unstructured":"Jordan VC, Dowse LJ: Tamoxifen as an antitumour agent: effect on oestrogen binding. J Endocrinol 68:297?303, 1976.","journal-title":"J Endocrinol"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0680305","volume":"68","author":"VC Jordan","year":"1976","unstructured":"Jordan VC, Koerner S: Tamoxifen as an antitumour agent: role of oestradiol and prolactin. J Endocrinol 68:305?310, 1976.","journal-title":"J Endocrinol"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.0680453","volume":"68","author":"VC Jordan","year":"1976","unstructured":"Jordan VC, Jaspan T: Tamoxifen as an antitumour agent: oestrogen binding as a predictive test for tumour response. J Endocrinol 68:453?460, 1976.","journal-title":"J Endocrinol"},{"key":"CR38","unstructured":"Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Rel Cancer (October supplement) pp 49?55, 1978."},{"key":"CR39","first-page":"19","volume-title":"Adjuvant Therapy of Cancer","author":"VC Jordan","year":"1979","unstructured":"Jordan VC, Dix CJ, Allen KE: The effectiveness of long term treatment in a laboratory model for adjuvant hormone therapy of breast cancer.In: Salmon SE, Jones SE (eds) Adjuvant Therapy of Cancer, Vol. 2. Grune and Stratton, New York, 1979, pp 19?26."},{"key":"CR40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-2964(80)90156-5","volume":"16","author":"VC Jordan","year":"1980","unstructured":"Jordan VC, Allen KE: Evaluation of the antitumour activity of the antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:231?251, 1980.","journal-title":"Eur J Cancer"},{"key":"CR41","first-page":"745","volume":"64","author":"VC Jordan","year":"1980","unstructured":"Jordan VC, Allen KE, Dix CJ: Pharmacology of tamoxifen in laboratory animals. Cancer Treat Rep 64:745?759, 1980.","journal-title":"Cancer Treat Rep"},{"issue":"Supplement","key":"CR42","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1007\/BF01855131","volume":"3","author":"VC Jordan","year":"1983","unstructured":"Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 3 (Supplement) S73-S86, 1983.","journal-title":"Breast Cancer Res Treat"},{"key":"CR43","first-page":"1256","volume":"i","author":"Ludwig Breast Cancer Study Group","year":"1985","unstructured":"Ludwig Breast Cancer Study Group: Randomized trial of chemoendocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast carcinoma and axillary node metastases. Lanceti:1256?1260, 1985.","journal-title":"Lancet"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0277-5379(85)90104-X","volume":"21","author":"G Ribeiro","year":"1985","unstructured":"Ribeiro G, Swindell R: The Christie Hospital tamoxifen (Nolvadex) adjuvant trial for operable breast carcinoma ? seven year results. Eur J Cancer Clin Oncol 21:897?900, 1985.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0140-6736(85)90966-3","volume":"i","author":"C Rose","year":"1985","unstructured":"Rose C, Thorpe SM, Anderson KW, Pederson BV, Mouridsen HT, Blichert-Toft M, Rasmussen BB: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. Lanceti:16?19, 1985.","journal-title":"Lancet"},{"key":"CR46","first-page":"836","volume":"i","author":"Nolvadex Adjuvant Trial Organization (NATO)","year":"1985","unstructured":"Nolvadex Adjuvant Trial Organization (NATO): Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Lanceti:836?840, 1985.","journal-title":"Lancet"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF01806795","volume":"7","author":"T Delozier","year":"1986","unstructured":"Delozier T, Julien JP, Juret P, Veynet C, Conette JE, Graic Y, Olliver JM, deRancieri E: Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial. Breast Cancer Res Treat 7:105?119, 1986.","journal-title":"Breast Cancer Res Treat"},{"key":"CR48","first-page":"171","volume":"ii","author":"Breast Cancer Trials Committee, Scottish Cancer Trials Office","year":"1987","unstructured":"Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancetii:171?175, 1987.","journal-title":"Lancet"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:71?85, 1992.","journal-title":"Lancet"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/0003-4819-106-5-649","volume":"106","author":"B Fisher","year":"1987","unstructured":"Fisher B, and National Surgical Adjuvant Breast and Bowel Project investigators: Prolonging tamoxifen therapy for primary breast cancer. Ann Int Med 106:649?654, 1987.","journal-title":"Ann Int Med"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, and 50 other members of the NSABP: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 320:479?484, 1989.","journal-title":"N Engl J Med"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01806042","volume":"4","author":"DC Tormey","year":"1984","unstructured":"Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4:297?302, 1984.","journal-title":"Breast Cancer Res Treat"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1990.8.4.599","volume":"8","author":"HC Falkson","year":"1990","unstructured":"Falkson HC, Gray R, Wolberg WA, Gilchrist KW, Harris JE, Tormey DC, Falkson G: Adjuvant trials of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer. An Eastern Cooperative Oncology Group Phase III Study. J Clin Oncol 8:599?607, 1990.","journal-title":"J Clin Oncol"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1200\/JCO.1992.10.12.1848","volume":"10","author":"DC Tormey","year":"1992","unstructured":"Tormey DC, Gray R, Abeloff MD, Roseman L, Gilchrist KW, Barylak EJ, Stott P, Falkson G: Adjuvant therapy with doxorubicin regimen and long term tamoxifen in premenopausal breast cancer patients. An Eastern Cooperative Oncology Group Trial. J Clin Oncol 10:1848?1856, 1992.","journal-title":"J Clin Oncol"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01806132","volume":"10","author":"VC Jordan","year":"1987","unstructured":"Jordan VC, Phelps E, Lindgren JU: Effect of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 10:31?35, 1987.","journal-title":"Breast Cancer Res Treat"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1210\/endo-122-3-1146","volume":"122","author":"RT Turner","year":"1988","unstructured":"Turner RT, Wakley GK, Hannon KS, Bell NH: Tamoxifen inhibits osteoclast mediated resorption of trabecular bone in ovarian hormone-deficient rats. Endocrinology 122:1146?1150, 1988.","journal-title":"Endocrinology"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF01811242","volume":"12","author":"RR Love","year":"1988","unstructured":"Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297?302, 1988.","journal-title":"Breast Cancer Res Treat"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.1990.8.6.1019","volume":"8","author":"T Fornander","year":"1990","unstructured":"Fornander T, Rutqvist LE, Sjoberg HE, Blomqvist L, Mattson A, Glas U: Long term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019?1024, 1990.","journal-title":"J Clin Oncol"},{"key":"CR59","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/jnci\/81.14.1086","volume":"81","author":"S Turken","year":"1989","unstructured":"Turken S, Siris E, Seldin D, Floster E, Hyman G, Lindsay R: Effect of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 81:1086?1088, 1989.","journal-title":"J Natl Cancer Inst"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJM199203263261302","volume":"326","author":"RR Love","year":"1992","unstructured":"Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852?856, 1992.","journal-title":"N Engl J Med"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-6009(08)80220-6","volume":"22","author":"RL Ward","year":"1993","unstructured":"Ward RL, Morgan G, Dalley D, Kelley PJ: Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Min 22:87?94, 1993.","journal-title":"Bone Min"},{"key":"CR62","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.1994.12.5.992","volume":"12","author":"B Kristensen","year":"1994","unstructured":"Kristensen B, Ejlertsen B, Dalgaard P, Larsen L, Holmegaard SN, Transbol I, Mouridsen HT: Tamoxifen and bone metabolism in postmenopausal, low risk breast cancer patients: a randomized study. J Clin Oncol 12:992?997, 1994.","journal-title":"J Clin Oncol"},{"key":"CR63","volume-title":"Long-term Tamoxifen Treatment for Breast Cancer","year":"1994","unstructured":"Jordan VC (ed): Long-term Tamoxifen Treatment for Breast Cancer. University of Wisconsin Press, Madison, 1994."},{"key":"CR64","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0021-9150(84)90064-9","volume":"52","author":"S Rossner","year":"1984","unstructured":"Rossner S, Wallgren A: Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52:339?346, 1984.","journal-title":"Atherosclerosis"},{"key":"CR65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.1988.248","volume":"58","author":"PF Bruning","year":"1988","unstructured":"Bruning PF, Bonfrer JMG, Hart AAM: Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer 58:497?499, 1988.","journal-title":"Br J Cancer"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF01811244","volume":"12","author":"G Bertelli","year":"1988","unstructured":"Bertelli G, Pronzato P, Ameroso D: Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III. Breast Cancer Res Treat 12:307?310, 1988.","journal-title":"Breast Cancer Res Treat"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1210\/jcem-70-4-1132","volume":"70","author":"JD Bagdade","year":"1990","unstructured":"Bagdade JD, Wolter J, Subbaiah PV: Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 70:1132?1135, 1990.","journal-title":"J Clin Endocrinol Metab"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"860","DOI":"10.7326\/0003-4819-115-11-860","volume":"115","author":"RR Love","year":"1991","unstructured":"Love RR, Weibe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, Feyzi J, DeMets DC: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Int Med 115:860?864, 1991.","journal-title":"Ann Int Med"},{"key":"CR69","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1445-2197.1990.tb07454.x","volume":"60","author":"D Ingram","year":"1990","unstructured":"Ingram D: Tamoxifen use, oestrogen binding, and serum lipids in postmenopausal women with breast cancer. Aust NZ J Surg 60:673?675, 1990.","journal-title":"Aust NZ J Surg"},{"key":"CR70","first-page":"15","volume":"29A","author":"J Cuzick","year":"1992","unstructured":"Cuzick J, Allen D, Baum M, Barrett J, Clark G, Kakkar V, Melissari E, Moniz C, Moore J, Parsons V, Pemberton K, Pitt P, Richmond W, Houghton J, Riley D: Long-term effects of tamoxifen. Eur J Cancer 29A:15?21, 1992.","journal-title":"Eur J Cancer"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0009-8981(93)90061-8","volume":"223","author":"AM Dnistrian","year":"1993","unstructured":"Dnistrian AM, Schwartz MK, Greenberg EJ: Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin Chim Acta 223:43?52, 1993.","journal-title":"Clin Chim Acta"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/1097-0142(19940201)73:3<659::AID-CNCR2820730325>3.0.CO;2-H","volume":"73","author":"M Thangaraju","year":"1994","unstructured":"Thangaraju M, Kumar K, Gandhirajan R, Sachdanadan P: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73:659?663, 1994.","journal-title":"Cancer"},{"key":"CR73","first-page":"57","volume-title":"Long-Term Tamoxifen Treatment for Breast Cancer","author":"RR Love","year":"1994","unstructured":"Love RR: Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women.In: Jordan VC (ed) Long-Term Tamoxifen Treatment for Breast Cancer. University of Wisconsin Press, Madison, 1994, pp 57?81."},{"key":"CR74","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/bmj.303.6800.435","volume":"303","author":"CC McDonald","year":"1991","unstructured":"McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 303:435?437, 1991.","journal-title":"Br Med J"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jnci\/83.7.492","volume":"83","author":"VC Jordan","year":"1991","unstructured":"Jordan VC, Lababidi MK, Langan-Fahey S: Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83:492?496, 1991.","journal-title":"J Natl Cancer Inst"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3181\/00379727-208-43846C","volume":"208","author":"VC Jordan","year":"1995","unstructured":"Jordan VC: Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144?149, 1995.","journal-title":"Proc Soc Exp Biol Med"},{"key":"CR77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright, Goldgar D, Wiseman R, Kamb A, Skolnick MH: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66?71, 1994.","journal-title":"Science"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/0959-8049(94)00455-E","volume":"30A","author":"DJ Bishop","year":"1994","unstructured":"Bishop DJ: BRCA1, BRCA2, BRCA3... a myriad of breast cancer genes. Eur J Cancer 30A:1738?1739, 1994.","journal-title":"Eur J Cancer"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/bjc.1989.235","volume":"60","author":"TJ Powles","year":"1989","unstructured":"Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, Dowsett M, McKinna JA, Nash AG, Sinnett HD, Tillyer CR, Treleaven JG: A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126?133, 1989.","journal-title":"Br J Cancer"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/0277-5379(90)90116-B","volume":"26","author":"TJ Powles","year":"1990","unstructured":"Powles TJ, Tillyer CP, Jones AL, Ashley SE, Treleaven J, Davey JB, McKinna JA: Prevention of breast cancer with tamoxifen ? an update on the Royal Marsden pilot program. Eur J Cancer 26:680?684, 1990.","journal-title":"Eur J Cancer"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00689678","volume":"31","author":"TJ Powles","year":"1994","unstructured":"Powles TJ, Jones AL, Ashley SE, O'Brien MER, Tidy VA, Treleaven J, Cosgrove D, Nash AG, Sacks N, Baum M, McKinna JA, Davey JB: The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73?82, 1994.","journal-title":"Breast Cancer Res Treat"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/S0140-6736(94)92466-X","volume":"343","author":"RP Kedar","year":"1994","unstructured":"Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SF, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 343:1318?1321, 1994.","journal-title":"Lancet"},{"key":"CR83","first-page":"978","volume":"343","author":"TJ Powles","year":"1994","unstructured":"Powles TJ, Ashley S: Endometrial cancer during tamoxifen treatment. Lancet 343:978, 1994.","journal-title":"Lancet"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Binton LA, Byar DP, Carle DK, Green SB: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879?1886, 1989.","journal-title":"J Natl Cancer Inst"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/jnci\/84.20.1555","volume":"84","author":"C Vanchieri","year":"1992","unstructured":"Vanchieri C: Breast cancer study initiated in Italy. J Natl Cancer Inst 84:1555?1556, 1992.","journal-title":"J Natl Cancer Inst"},{"key":"CR86","first-page":"812","volume":"48","author":"MM Gottardis","year":"1988","unstructured":"Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48:812?815, 1988.","journal-title":"Cancer Res"},{"key":"CR87","unstructured":"Assikis VJ, Jordan VC: Gynecological effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet (in press)."},{"key":"CR88","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1993.11.3.485","volume":"11","author":"U Magriples","year":"1993","unstructured":"Magriples U, Naftolin F, Schwartz PE, Carcangiu JL: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485?490, 1993.","journal-title":"J Clin Oncol"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","volume":"i","author":"T Fornander","year":"1989","unstructured":"Fornander T, Rutqvist LE, Cedermark BV, Glas U, Mattsson A, Silfversw\u00e4rd C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lanceti:117?120, 1989.","journal-title":"Lancet"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/jnci\/85.22.1850","volume":"85","author":"T Fornander","year":"1993","unstructured":"Fornander T, Hellstrom AC, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850?1855, 1993.","journal-title":"J Natl Cancer Inst"},{"key":"CR91","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/0959-8049(94)00349-A","volume":"30A","author":"VC Jordan","year":"1994","unstructured":"Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A:1714?1721, 1994.","journal-title":"Eur J Cancer"},{"key":"CR92","unstructured":"Jordan VC, Assikis VJ: Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res (in press)."},{"key":"CR93","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"80","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, and other NSABP contributors: Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSAB P) B-14. J Natl Cancer Inst 80:527?537, 1994.","journal-title":"J Natl Cancer Inst"},{"key":"CR94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/gyno.1994.1271","volume":"55","author":"RR Barakat","year":"1994","unstructured":"Barakat RR, Wong G, Curtin JP, Vlamio V, Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histological features. Gynecol Oncol 55:164?168, 1994.","journal-title":"Gynecol Oncol"},{"key":"CR95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004347-199501000-00003","volume":"14","author":"G Dallenbach-Hellweg","year":"1994","unstructured":"Dallenbach-Hellweg G, Hahn U: Mucinous and clear cell adenocarcinomas of the endometrium in patients receiving antiestrogens (tamoxifen) and gestagens. Int J Gynecol Pathol 14:7?15, 1994.","journal-title":"Int J Gynecol Pathol"},{"key":"CR96","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1677\/joe.0.0750305","volume":"75","author":"VC Jordan","year":"1977","unstructured":"Jordan VC, Collins MM, Rowsby L, Prestwich G: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305?316, 1977.","journal-title":"J Endocrinol"},{"key":"CR97","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/15287397809529666","volume":"4","author":"VC Jordan","year":"1978","unstructured":"Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L: Non-steroidal antiestrogens: their biological effects and potential mechanisms of action. J Toxicol Environ Health 4:364?390, 1978.","journal-title":"J Toxicol Environ Health"},{"key":"CR98","first-page":"7193","volume":"48","author":"C Malet","year":"1988","unstructured":"Malet C, Gompel A, Spritzer P, Bicout N, Yaneva H, Mowzowicz I, Kutten N, Mauvais-Jarvis P: Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture. Cancer Res 48:7193?7199, 1988.","journal-title":"Cancer Res"},{"key":"CR99","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0277-5379(90)90241-K","volume":"26","author":"T Toko","year":"1990","unstructured":"Toko T, Sugimoto Y, Matsuo KI, Yamasaki R, Takeda S, Wiereba K, Asao T, Yamada Y: TAT-59, a new triphenylethylene derivative with antitumor activity against hormone dependent tumors. Eur J Cancer 26:397?404, 1990.","journal-title":"Eur J Cancer"},{"key":"CR100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0304-3835(94)90364-6","volume":"84","author":"M Hasmann","year":"1994","unstructured":"Hasmann M, Rattel B, Loser R: Preclinical data for droloxifene. Cancer Lett 84:101?116, 1994.","journal-title":"Cancer Lett"},{"key":"CR101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF00689679","volume":"31","author":"W Rauschning","year":"1994","unstructured":"Rauschning W, Pritchard KI: Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat 31:83?94, 1994.","journal-title":"Breast Cancer Res Treat"},{"key":"CR102","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2964(81)90036-0","volume":"17","author":"VC Jordan","year":"1981","unstructured":"Jordan VC, Fenuik L, Allen KE, Cotton RC, Richardson DN, Walpole AL, Bowler J: Structural derivatives of tamoxifen and oestradiol 3 methyl ether as potential alkylating antiestrogens. Eur J Cancer Clin Oncol 17:193?200, 1981.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR103","doi-asserted-by":"crossref","first-page":"8221","DOI":"10.1016\/S0021-9258(17)34385-5","volume":"253","author":"R Bucourt","year":"1978","unstructured":"Bucourt R, Vignau M, Torelli V, Richard-Foy H, Geynet C, Secco-Millet C, Redeuilh G, Bailieu EE: New biospecific adsorbents for the purification of estradiol receptor. J Biol Chem 253:8221?8228, 1978.","journal-title":"J Biol Chem"},{"key":"CR104","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.112R007","volume":"112","author":"AE Wakeling","year":"1987","unstructured":"Wakeling AE, Bowler J: Steroidal pure antiestrogens. J Endocrinol 112:R7-R10, 1987.","journal-title":"J Endocrinol"},{"key":"CR105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0039-128X(89)90076-7","volume":"54","author":"J Bowler","year":"1989","unstructured":"Bowler J, Lilley TJ, Pittman JD, Wakeling AE: Novel steroidal pure antiestrogens. Steroids 54:71?99, 1989.","journal-title":"Steroids"},{"key":"CR106","first-page":"3867","volume":"51","author":"AE Wakeling","year":"1991","unstructured":"Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867?3873, 1991.","journal-title":"Cancer Res"},{"key":"CR107","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0277-5379(87)90154-4","volume":"232","author":"CK Osborne","year":"1987","unstructured":"Osborne CK, Coronado EB, Robinson JP: Human breast cancer in athymic nude mice: cytostatic effects of long-term antiestrogenic activity. Eur J Cancer Clin Oncol 232:1189?1196, 1987.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"CR108","first-page":"5183","volume":"48","author":"MM Gottardis","year":"1988","unstructured":"Gottardis MM, Jordan VC: Development of tamoxifen stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48:5183?5187, 1988.","journal-title":"Cancer Res"},{"key":"CR109","first-page":"4765","volume":"49","author":"MM Gottardis","year":"1989","unstructured":"Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growthin vivo andin vitro. Cancer Res 49:4765?4769, 1989.","journal-title":"Cancer Res"},{"key":"CR110","first-page":"4090","volume":"49","author":"MM Gottardis","year":"1989","unstructured":"Gottardis MM, Jiang SY, Jeng MH, Jordan VC: Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49:4090?4093, 1989.","journal-title":"Cancer Res"},{"key":"CR111","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00685924","volume":"34","author":"CK Osborne","year":"1994","unstructured":"Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89?95, 1994.","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR112","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oxfordjournals.annonc.a058279","volume":"3","author":"VC Jordan","year":"1992","unstructured":"Jordan VC: A therapeutic withdrawal can make a strategic advance. Ann Oncol 3:587?588, 1992.","journal-title":"Ann Oncol"},{"key":"CR113","first-page":"408","volume":"54","author":"DJ DeFriend","year":"1994","unstructured":"DeFriend DJ, Howell A, Nicholson RI, Andersen E, Dowsett M, Marbel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE: Investigation of a pure new antiestrogen (ICI 182,780) in women with primary breast cancer. Cancer Res 54:408?414, 1994.","journal-title":"Cancer Res"},{"key":"CR114","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1677\/erc.0.0010005","volume":"1","author":"RI Nicholson","year":"1994","unstructured":"Nicholson RI, Francis AB, McClelland RA, Manning DL, Gee JMW: Pure anti-oestrogens (ICI 164,384 and ICI 182,780) and breast cancer: is the attainment of complete estrogen withdrawal worthwhile? Rev Endocr Rel Cancer 1:5?17, 1994.","journal-title":"Rev Endocr Rel Cancer"},{"key":"CR115","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1677\/joe.0.1350239","volume":"135","author":"M Dukes","year":"1992","unstructured":"Dukes M, Miller D, Wakeling AE, Waterton JC: Antiuterotrophic effect of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 135:239?247, 1992.","journal-title":"J Endocrinol"},{"key":"CR116","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1677\/joe.0.1380203","volume":"138","author":"M Dukes","year":"1993","unstructured":"Dukes M, Waterton JC, Wakeling AE: Antiuterotrophic effect of pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 138:203?210, 1993.","journal-title":"J Endocrinol"},{"key":"CR117","first-page":"4177","volume":"50","author":"LJ Lerner","year":"1990","unstructured":"Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 50:4177?4189, 1990.","journal-title":"Cancer Res"},{"key":"CR118","unstructured":"Morrow M, Jordan VC: Risk factors and the prevention of breast cancer with tamoxifen.In: Fentiman IS, Taylor-Papadimitriou J (eds) Breast Cancer. Cancer Surveys, Vol. 18, Cold Spring Harbor Laboratory Press, 1993, pp 211?230."},{"key":"CR119","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0024-3205(83)90935-9","volume":"32","author":"LJ Black","year":"1983","unstructured":"Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with a new benzothiopene-derived antiestrogen. Life Sci 32:1031?1036 1983.","journal-title":"Life Sci"},{"key":"CR120","first-page":"4020","volume":"47","author":"MM Gottardis","year":"1981","unstructured":"Gottardis MM, Jordan VC: The antitumor action of keoxifene and tamoxifen in the N-nitrosomethylureainduced rat mammary carcinoma model. Cancer Res 47:4020?4024, 1981.","journal-title":"Cancer Res"},{"key":"CR121","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1172\/JCI116985","volume":"93","author":"LJ Black","year":"1994","unstructured":"Black LJ, Sato M, Towley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kaufman RF, Bersch WR, Frolik, CA, Termine JD, Bryant HD: Raloxifene (LY139481HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypotrophy in ovariectomized rats. J Clin Invest 93:63?69, 1994.","journal-title":"J Clin Invest"},{"key":"CR122","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/6.suppl_3.S29","volume":"6","author":"VC Jordan","year":"1995","unstructured":"Jordan VC: What if ICI 46,474 (tamoxifen) had been found to produce rat liver tumors in 1973? Ann Oncol 6:29?34, 1995.","journal-title":"Ann Oncol"},{"key":"CR123","doi-asserted-by":"crossref","unstructured":"Tellez C, Jordan VC: Hormonal treatment for advanced breast cancer.In: Bland K (ed) Surg Oncol Clin N America (in press).","DOI":"10.1016\/S1055-3207(18)30428-9"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00713399.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00713399\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00713399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T06:41:22Z","timestamp":1625035282000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00713399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995]]},"references-count":123,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1995]]}},"alternative-id":["BF00713399"],"URL":"https:\/\/doi.org\/10.1007\/bf00713399","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995]]}}}